CALCRL and migraine disorder: A recent evaluation by Porreca et al. (50) reported that for acute migraine treatment, small molecule CGRP-R antagonists only appear to be effective in women, while CGRP-R targeting antibodies are effective for migraine prevention in both male and female episodic patients.